Hypertonic Saline 3% Nebulizer versus intravenous hypertonic saline 3% in ARDS

Evaluation of the Use of Hypertonic Saline 3% Nebulizer versus intravenous hypertonic saline 3% to attenuate the Manifestations of Acute Respiratory Distress Syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR201909691980023

Enrollment

104

Registered

2019-09-25

Start date

2019-08-13

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory

Interventions

intravenous normal saline 0.9

nebulizer

neublizer

intravenous

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: both sexes age of 18-60 years fulfilling Berlin definition of ARDS as follows:

Exclusion criteria

Exclusion criteria: Presence of heart failure or evidence of fluid overload renal failure hyperventilate patient refuse to anticipate

Design outcomes

Primary

Measure	Time frame
decrease in Lung injury score which was calculated every 24 hours	—

Secondary

Measure	Time frame
Incidence of the need for mechanical ventilation	—

Countries

Egypt

Contacts

Public Contactmohammed kamal

lecturer Ain shams university faculty of medicine

dr_medo2000@hotmail.com00201009998643

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026